贝伐单抗
PLGA公司
化学
血管生成
纳米颗粒
药物输送
聚乙二醇
表面改性
聚乙二醇化
体内
血管内皮生长因子
药理学
生物医学工程
体外
生物物理学
癌症研究
材料科学
纳米技术
医学
生物化学
外科
化疗
生物
血管内皮生长因子受体
生物技术
物理化学
作者
Giulia De Negri Atanasio,Pier Francesco Ferrari,Ana Baião,Patrizia Perego,Bruno Sarmento,Domenico Palombo,Roberta Campardelli
标识
DOI:10.1016/j.ijbiomac.2022.08.063
摘要
Atherosclerosis represents one of the main causes of death in the Western world. It is a multifactorial pathology characterized by lesions that reduce the lumen of the vessels causing serious clinical events. The extra-domain B of fibronectin is overexpressed during angiogenesis and in tissues undergoing growth and extensive remodeling, i.e., atherosclerotic plaque. Bevacizumab is a recombinant humanized monoclonal antibody that can play a central role against angiogenesis reducing the risk associated with this process in atherosclerosis. In this work, an innovative nanosystem for the targeted delivery of bevacizumab to the atherosclerotic lesion is proposed. A production protocol for poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles loaded with bevacizumab and functionalized with immunouteroglobin-1 was designed. Once functionalized nanoparticles with immunouteroglobin-1 were produced, they were characterized in terms of morphology, mean diameter, ζ-potential, association and conjugation efficiencies, bevacizumab release profile, both in phosphate buffered saline and in serum, bevacizumab stability after release, cytocompatibility, and hemocompatibility. Nanoparticle mean diameter was in the range of 217-265 nm, their surface charge was between -22 and -8 mV, and the association and conjugation efficiencies of about 76 and 59 %, respectively. Fourier transform infrared spectroscopy analysis confirmed the functionalization of their surface with immunouteroglobin-1. In vitro assays showed that the studied nanoparticles were cytocompatible, once in contact with human endothelial and murine macrophage cell lines up to 72 h, and hemocompatible, once in contact with red blood cells, at different concentrations of encapsulated bevacizumab (0.1, 1, 10, and 100 μg/mL).
科研通智能强力驱动
Strongly Powered by AbleSci AI